NL-OMON33920
Not Yet Recruiting
N/A
Validation of circulating tumor cells (CTC) detection techniques in patients with advanced solid tumors - CTC detection in advanced solid tumors
Antoni van Leeuwenhoek Ziekenhuis0 sites200 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Advanced cancer
- Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Enrollment
- 200
- Status
- Not Yet Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who are treated for advanced solid tumors;
- •Age of 18 years or older;
- •Able and willing to give written informed consent;
- •Able and willing to undergo veni\-puncture;
- •Life expectancy of 3 months or more;
- •WHO performance status of 0, 1 or 2;
Exclusion Criteria
- •Any condition that may interfere with the study protocol
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Detection of circulating tumor cells (CTC) with novel viral marker (OBP-401) for patients with prostate cancerProstate cancerJPRN-UMIN000010410Department of Urology, Kobe university graduate school of medicine50
Recruiting
N/A
Determining Circulating Tumour Cells (CTC) and other rare cells in cancer patients and for early detection screeningACTRN12614001143617Dr Karin Ried2,000
Completed
N/A
A study on the detection of circulating tumor cells (CTC) in patients with resected pulmonary metastases from colorectal cancer and its clinical significance as a biomarkerPulmonary metastases from colorectal cancerJPRN-UMIN000017460Kawasaki Medical School, Department of General Thoracic Surgery5
Recruiting
N/A
A study on the detection of circulating tumor cells (CTCs) in patients with hepatocellular carcinoma and its clinical significanceJPRN-UMIN000025989Hiroshima university100
Active, Not Recruiting
N/A
Evaluation of Circulating Tumors Cells (CTCs) as Potential Surrogate Marker for Further Definition und Subclassification of non metastatic High-Risk Castration Resistant Prostate Cancer Patientsprostate cancerC61Malignant neoplasm of prostateDRKS00008554OnkoDataMed GmbH5